Michael is a dynamic leader with a strong track record of success in the pharmaceutical and biotechnology industries. As Inoviv’s CEO, Michael drives the company’s strategic vision and growth. Prior to this, Michael played instrumental roles in securing multi-million dollar deals within the pharmaceutical sector. He has project-managed over $10 million worth of technology projects supporting drug trials at renowned companies such as GSK, Novartis, and Merck. Michael’s keen understanding of the industry landscape and his ability to navigate complex projects have contributed significantly to the success of these endeavors.